Sleeping bruxism treatment market is expected to register a CAGR of 5.95 % with USD 934.90 Million by 2030
Sleeping Bruxism Treatment Market size is projected to be worth USD 934.90 million by 2030, registering a CAGR of 5.95% during the forecast period (2021 - 2030)
Sleeping bruxism is a chronic sleep related movement disorder which is characterized by clenching of the jaw, teeth and cheek during sleep. The common symptom of this disease is tooth wear on the upper front teeth. It can also cause soreness in the neck muscle and headaches. The treatment of sleep bruxism includes holding dental guard to keep patient mouth closed during sleep which reduces risk of anxiety or stress.
The growth of the global sleeping bruxism treatment market is attributed to the increasing prevalence of sleep bruxism, growing child population, rising prevalence of obstructive sleep apnea and lifestyle changes. However, limited availability of treatment options is hampering the market growth. Also, untapped markets in Asia-Pacific provide viable opportunities for market growth in the future.
The stress caused due to variable factors during the pandemic increased the demand for sleeping bruxism treatment. The health experts found that stress, anxiety, insomnia are the major factors that augmented the number of sleeping bruxism cases. Sleeping bruxism may lead to tooth fractures in serious cases. Moreover, the dental appointments and consulting services rose in the mid of the pandemic as a large number of the patients were experiencing pain and teeth grinding issues. These factors accelerated the demand for sleeping bruxism treatment across the world. However, improvement in networking and communication infrastructure supported the telehealth platforms, thereby helping patients and doctors in face-to-face consulting. The hospitals, dental clinics, and ambulatory centers are functional for emergency cases such as immediate discomfort in the jaw joints, tooth fractures, and increased agony in the facial muscular worldwide. Hence, there is a rise in the immediate sleeping bruxism treatment, including Botox injections, anti-anxiety/anti-depressants drugs, bite guards, nonsteroidal anti-inflammatory drugs (NSAIDs), and heat packs.
|Market Size||2027: USD 934.90 Million|
|Historical Data||2018 & 2019|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Treatment, Test Type, End User, and Region|
|Geographies Covered||Americas, Europe, Asia-Pacific, and Middle East and Africa|
|Key Vendors||Ivoclar Vivadent AG (Liechtenstein), Ipsen S.A. (France), Merz Pharma GmbH & Co. KGaA (Germany), Carestream Dental (US), Akervall Technologies Inc (US), Planmeca Oy (Finland), Randmark Dental Products, LLC (US), S4S (UK) Limited (UK), Patterson Dental Supply, Inc (US), Henry Schein, Inc (US), Pfizer, Inc (US), and others|
|Key Market Opportunities||• Untapped Markets in Asia-Pacific|
|Key Market Drivers||• Increasing prevalence of sleep bruxism • Growing child population • Rising prevalence of obstructive sleep apnea • Lifestyle changes|
Sleeping bruxism treatment market projected to grow at approximately 5.95% CAGR during the assessment period (2020-2030).
The valuation of the sleeping bruxism treatment market is estimated to increase to USD 934.90 MN by the end of 2030.
Increasing prevalence of the disorder and growing funding & healthcare insurance coverage, are major tailwinds pushing the growth of the sleeping bruxism treatment market.
North America holds the largest share in the sleeping bruxism treatment market, followed by Europe and the Asia Pacific, respectively.
Ipsen Biopharmaceuticals, Inc., Pfizer Inc., Ivoclar Vivadent AG, Henry Schein, Inc., Merz Pharma GmbH & Co. KGaA, Carestream Dental, Patterson Dental Supply, Inc., S4S Dental Laboratory, Akervall Technologies Inc., PLANMECA OY, and Randmark Dental Products, LLC, are some of the top players operating in the global sleeping bruxism treatment market.